Skip to main content
. 2021 Nov 22;12:780937. doi: 10.3389/fphar.2021.780937

TABLE 6.

Simulated exposure changes of apatinib in patients with HI and RI

Subjects Cmax (ng/ml) AUC (ng/ml·h) Ratio
RCmax RAUC
HVs 911.56 7,934.66 /
HI CP-A 892.54 8,641.86 1.02 1.09
HI CP-B 1,402.36 17,880.77 1.54 2.25
HI CP-C 1,524.33 24,141.57 1.67 3.04
Moderate RIs 894.98 8,449.86 1.02 1.06
Severe RIs 820.29 8,050.40 1.11 1.01